BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
3 Hu M, Tomlinson B. Pharmacokinetic evaluation of lanreotide. Expert Opinion on Drug Metabolism & Toxicology 2010;6:1301-12. [DOI: 10.1517/17425255.2010.513700] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
4 Ewertsen C, Henriksen BM, Hansen CP, Knigge U. Synchronous gastric neuroendocrine carcinoma and hepatocellular carcinoma: a case report. BMJ Case Rep 2009;2009:bcr03. [PMID: 21918674 DOI: 10.1136/bcr.03.2009.1667] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Yang XW, Wang XL, Cao LQ, Jiang XF, Peng HP, Lin SM, Xue P, Chen D. Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol Res 2012;42:494-501. [PMID: 22221825 DOI: 10.1111/j.1872-034X.2011.00947.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
7 Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011; 17(3): 313-321 [PMID: 21253389 DOI: 10.3748/wjg.v17.i3.313] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
8 Voumvouraki A, Notas G, Koulentaki M, Georgiadou M, Klironomos S, Kouroumalis E. Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies. Eur J Clin Invest. 2012;42:815-822. [PMID: 22304651 DOI: 10.1111/j.1365-2362.2012.02647.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
9 Del Rio-Moreno M, Alors-Perez E, Borges de Souza P, Prados-Gonzalez ME, CastaÑo JP, Luque RM, Gahete MD. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Transl Res 2019;211:147-60. [PMID: 30904441 DOI: 10.1016/j.trsl.2019.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
10 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
11 Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Avila MA. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel) 2011;3:2444-61. [PMID: 24212818 DOI: 10.3390/cancers3022444] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit. 2011;17:RA169-RA176. [PMID: 21804474 DOI: 10.12659/msm.881892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
13 Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. [PMID: 21985599 DOI: 10.1186/1479-5876-9-171] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 13.0] [Reference Citation Analysis]
14 Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol. 2010;66:837-844. [PMID: 20041325 DOI: 10.1007/s00280-009-1226-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
15 Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2:e150. [PMID: 21525937 DOI: 10.1038/cddis.2011.34] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
16 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
17 Georgiadou M, Notas G, Xidakis C, Drygiannakis I, Sfakianaki O, Klironomos S, Valatas V, Kouroumalis E. TNF receptors in Kupffer cells. Journal of Receptors and Signal Transduction 2011;31:291-8. [DOI: 10.3109/10799893.2011.586354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Shaaban S, Negm A, Ibrahim EE, Elrazak AA. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev 2014;8:246. [PMID: 25992234 DOI: 10.4081/oncol.2014.246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]